Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,544,999
-
Share change
-
+25,036
-
Total reported value
-
$5,044,761
-
Put/Call ratio
-
467%
-
Price per share
-
$3.26
-
Number of holders
-
24
-
Value change
-
+$81,758
-
Number of buys
-
10
-
Number of sells
-
9
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2023
As of 31 Dec 2023,
Gain Therapeutics, Inc. - COM (GANX) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,544,999 shares.
The largest 10 holders included
GREENLIGHT CAPITAL INC, ROYAL BANK OF CANADA, GEODE CAPITAL MANAGEMENT, LLC, CM Management, LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, PRELUDE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.